Collegium Pharma (COLL)

$49.58 +0.73 (1.49%)
Market Cap 1.54B
Revenue (ttm) 631.45M
Net Income (ttm) 69.19M
EPS (ttm) N/A
PE Ratio 7.64
Forward PE 7.20
Profit Margin 10.96%
Debt to Equity Ratio 2.07
Volume 199,000
Avg Vol 516,558
Day's Range N/A - N/A
Shares Out 31.61M
Stochastic %K 84%
Beta 0.61
Analysts Strong Sell
Price Target $48.67

Company Profile

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. The company's portfolio includes Jornay PM, a central nervous system stimulant prescription medicine that contains methylphenidate HCl for the treatment of attention deficit hyperactivity disorder; Belbuca, a buccal film that contains buprenorphine for severe and persistent pain that requires an extended treatment period; Xtampza ER, an abuse-dete...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 781 713 3699
Address:
100 Technology Center Drive, Suite 300, Stoughton, United States
jewell69
jewell69 Dec. 25 at 1:17 AM
$COLL did everybody see it was up 6.5% today 12/24/25
0 · Reply
volflux
volflux Dec. 18 at 12:55 PM
$COLL
0 · Reply
JarvisFlow
JarvisFlow Dec. 9 at 3:37 PM
Barclays has adjusted their stance on Collegium Pharmaceutical ( $COLL ), setting the rating to Overweight with a target price of 58.
0 · Reply
Estimize
Estimize Nov. 24 at 1:03 PM
Wall St is expecting 2.14 EPS for $COLL Q4 [Reporting 02/19 BMO] http://www.estimize.com/intro/coll?chart=historical&metric_name=eps&utm_co
0 · Reply
KirRoyalTrader
KirRoyalTrader Nov. 23 at 10:02 PM
$UVE $INVA $COLL $APPN
0 · Reply
evanmedeiros
evanmedeiros Nov. 23 at 5:10 PM
Nice high tight flag setting up here in Collegium Pharmaceutical. Watchlists still loaded with pharma stocks as technology continues its sell off. Chart found from @InvestorsBusinessDaily MarketSurge https://research.investors.com/stock-quotes/nasdaq-COLL-inc-COLL.htm?utm_source=Evan_Medeiros&utm_medium=stocktwits&utm_campaign=SOCIAL+INFLUENCER&utm_id=SCINFLUENCER&utm_content=leaderboard#performance%3Fsrc=A00616 $COLL #IBDPartner
0 · Reply
ZacksResearch
ZacksResearch Nov. 21 at 1:14 PM
2025 could be the momentum shift $COLL investors have been waiting for. Bold buybacks, a refreshed board, and an expanding ADHD push are all lining up to make this a truly dynamic, transformative year. Full breakdown here 👉 https://www.zacks.com/stock/news/2794020/why-2025-is-a-dynamic-and-transformative-year-for-collegium?cid=sm-stocktwits-2-2794020-teaser-21968&ADID=SYND_STOCKTWITS_TWEET_2_2794020_TEASER_21968
0 · Reply
ZacksResearch
ZacksResearch Nov. 21 at 12:14 PM
$COLL outshines with a 53.4% YTD gain! 🚀 ✨ Q3 2025 adjusted EPS of $2.25 beats the Zacks Consensus Estimate of $1.88. 📊 Revenue for Q3 2025 hits $209.36M, topping consensus & improving from $159.3M a year ago. 💪 Zacks Rank #1 (Strong Buy) highlights their strategic growth initiatives. Discover the full growth story here 👉 https://www.zacks.com/stock/news/2794020/why-2025-is-a-dynamic-and-transformative-year-for-collegium?cid=sm-stocktwits-2-2794020-body-21967&ADID=SYND_STOCKTWITS_TWEET_2_2794020_BODY_21967
0 · Reply
JR603
JR603 Nov. 12 at 10:14 PM
$COLL Could this be a BO? It's tempting to cash out after all these LONG years ..... BUT what if it's going to be offered to be bought at a 50% premium? That would be just my luck!!!
1 · Reply
Itinerant
Itinerant Nov. 7 at 9:55 PM
$COLL I understand that some investors fear the risk of the opiod litigation and its potential damage to the valuation of COLL. I have added $500 million of such cost into the balance sheet of COLL, and I want to tell you that such a liability is not of serious consequence to the overall valuation of COLL. The company is substantially under valued and can absorb such a settlement cost without difficulty. Of course, I do not really know what such a settlement might prove to be. I am just guessing a number. But you get the idea. Having said that, the market will likely over react to any such settlement, as the market almost always over reacts. JMO
0 · Reply
Latest News on COLL
Collegium to Participate in Upcoming Investor Conferences

Nov 12, 2025, 8:00 AM EST - 6 weeks ago

Collegium to Participate in Upcoming Investor Conferences

Collegium Pharmaceutical: Another Solid Quarter

Nov 10, 2025, 4:27 PM EST - 6 weeks ago

Collegium Pharmaceutical: Another Solid Quarter

Collegium Pharmaceutical, Inc. (COLL) Q3 2025 Earnings Call Transcript

Nov 6, 2025, 10:06 PM EST - 6 weeks ago

Collegium Pharmaceutical, Inc. (COLL) Q3 2025 Earnings Call Transcript

Collegium Reports Third Quarter 2025 Financial Results; Raises 2025 Guidance

Nov 6, 2025, 7:30 AM EST - 6 weeks ago

Collegium Reports Third Quarter 2025 Financial Results; Raises 2025 Guidance

Knight Therapeutics Announces Launch of JORNAY PM™ in Canada

Oct 30, 2025, 5:15 PM EDT - 7 weeks ago

Knight Therapeutics Announces Launch of JORNAY PM™ in Canada

Collegium to Report Third Quarter 2025 Financial Results on November 6, 2025

Oct 23, 2025, 8:00 AM EDT - 2 months ago

Collegium to Report Third Quarter 2025 Financial Results on November 6, 2025

Collegium Announces Poster Presentations at the American Academy of Child & Adolescent Psychiatry and Neuroscience Education Institute Conferences

Oct 22, 2025, 8:00 AM EDT - 2 months ago

Collegium Announces Poster Presentations at the American Academy of Child & Adolescent Psychiatry and Neuroscience Education Institute Conferences

Collegium to Celebrate 10-Year Anniversary with Nasdaq Opening Bell Ringing

Oct 13, 2025, 8:00 AM EDT - 2 months ago

Collegium to Celebrate 10-Year Anniversary with Nasdaq Opening Bell Ringing

Collegium Pharmaceutical, Inc. (COLL) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 8, 2025, 5:03 PM EDT - 3 months ago

Collegium Pharmaceutical, Inc. (COLL) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Collegium to Present Nine Real-World Data Posters at PAINWeek 2025 Annual Meeting

Aug 25, 2025, 8:00 AM EDT - 4 months ago

Collegium to Present Nine Real-World Data Posters at PAINWeek 2025 Annual Meeting

Collegium Pharmaceutical, Inc. (COLL) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 2:00 PM EDT - 4 months ago

Collegium Pharmaceutical, Inc. (COLL) Q2 2025 Earnings Call Transcript

Collegium Reports Second Quarter 2025 Financial Results; Raises 2025 Outlook

Aug 7, 2025, 7:30 AM EDT - 4 months ago

Collegium Reports Second Quarter 2025 Financial Results; Raises 2025 Outlook

Collegium to Report Second Quarter 2025 Financial Results on August 7, 2025

Jul 24, 2025, 8:00 AM EDT - 5 months ago

Collegium to Report Second Quarter 2025 Financial Results on August 7, 2025

Collegium Announces $150 Million Share Repurchase Program

Jul 7, 2025, 8:00 AM EDT - 6 months ago

Collegium Announces $150 Million Share Repurchase Program

Collegium Pharmaceutical: Stock Deserves A "Buy" Call On Undervaluation Of ADHD Drug

Jun 30, 2025, 2:53 PM EDT - 6 months ago

Collegium Pharmaceutical: Stock Deserves A "Buy" Call On Undervaluation Of ADHD Drug

Collegium Announces $25 Million Accelerated Share Repurchase Program

May 12, 2025, 8:05 AM EDT - 8 months ago

Collegium Announces $25 Million Accelerated Share Repurchase Program

Collegium Pharmaceutical, Inc. (COLL) Q1 2025 Earnings Call Transcript

May 9, 2025, 2:04 AM EDT - 8 months ago

Collegium Pharmaceutical, Inc. (COLL) Q1 2025 Earnings Call Transcript

Collegium Reports First Quarter 2025 Financial Results and Highlights Recent Company Progress

May 8, 2025, 4:01 PM EDT - 8 months ago

Collegium Reports First Quarter 2025 Financial Results and Highlights Recent Company Progress

Collegium to Report First Quarter 2025 Financial Results on May 8, 2025

Apr 24, 2025, 8:00 AM EDT - 8 months ago

Collegium to Report First Quarter 2025 Financial Results on May 8, 2025

Collegium to Participate in 24th Annual Needham Virtual Healthcare Conference

Apr 1, 2025, 8:00 AM EDT - 9 months ago

Collegium to Participate in 24th Annual Needham Virtual Healthcare Conference

Collegium to Present Real-World Data at PainConnect 2025, the American Academy of Pain Medicine's Annual Meeting

Mar 27, 2025, 8:00 AM EDT - 9 months ago

Collegium to Present Real-World Data at PainConnect 2025, the American Academy of Pain Medicine's Annual Meeting

Collegium Announces Updates to its Board of Directors and Executive Leadership Team

Mar 17, 2025, 7:00 AM EDT - 10 months ago

Collegium Announces Updates to its Board of Directors and Executive Leadership Team

Collegium Announces Poster Presentations at the 2025 National Association of Pediatric Nurse Practitioners National Conference on Pediatric Health Care

Mar 10, 2025, 6:57 PM EDT - 10 months ago

Collegium Announces Poster Presentations at the 2025 National Association of Pediatric Nurse Practitioners National Conference on Pediatric Health Care

Collegium Pharmaceutical's Shareholders Might Be In For A Pain-Free 2025

Mar 9, 2025, 4:07 AM EDT - 10 months ago

Collegium Pharmaceutical's Shareholders Might Be In For A Pain-Free 2025

Collegium Pharmaceutical, Inc. (COLL) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 9:03 PM EST - 10 months ago

Collegium Pharmaceutical, Inc. (COLL) Q4 2024 Earnings Call Transcript

Collegium Reports Record Fourth Quarter and Full-Year 2024 Financial Results

Feb 27, 2025, 4:01 PM EST - 10 months ago

Collegium Reports Record Fourth Quarter and Full-Year 2024 Financial Results

Collegium to Report Fourth Quarter and Full-Year 2024 Financial Results on February 27, 2025

Feb 13, 2025, 8:00 AM EST - 11 months ago

Collegium to Report Fourth Quarter and Full-Year 2024 Financial Results on February 27, 2025

Collegium Provides 2025 Financial Guidance and Business Update

Jan 8, 2025, 8:00 AM EST - 1 year ago

Collegium Provides 2025 Financial Guidance and Business Update

Collegium Pharmaceutical: Strong Growth With Pain Management And ADHD Expansion

Nov 26, 2024, 8:00 AM EST - 1 year ago

Collegium Pharmaceutical: Strong Growth With Pain Management And ADHD Expansion

Knight Therapeutics Announces Health Canada Approval for JORNAY PM™ to Treat Attention-Deficit Hyperactivity Disorder (ADHD)

Nov 14, 2024, 4:30 PM EST - 1 year ago

Knight Therapeutics Announces Health Canada Approval for JORNAY PM™ to Treat Attention-Deficit Hyperactivity Disorder (ADHD)

Collegium Pharmaceutical, Inc. (COLL) Q3 2024 Earnings Call Transcript

Nov 8, 2024, 12:30 AM EST - 1 year ago

Collegium Pharmaceutical, Inc. (COLL) Q3 2024 Earnings Call Transcript

Collegium Reports Record Third Quarter 2024 Financial Results

Nov 7, 2024, 4:02 PM EST - 1 year ago

Collegium Reports Record Third Quarter 2024 Financial Results

Collegium to Participate in H.C. Wainwright 26th Annual Global Investment Conference

Aug 30, 2024, 8:00 AM EDT - 1 year ago

Collegium to Participate in H.C. Wainwright 26th Annual Global Investment Conference

Collegium Pharmaceutical, Inc. (COLL) Q2 2024 Earnings Call Transcript

Aug 8, 2024, 9:30 PM EDT - 1 year ago

Collegium Pharmaceutical, Inc. (COLL) Q2 2024 Earnings Call Transcript

Collegium Reports Second Quarter 2024 Financial Results

Aug 8, 2024, 4:01 PM EDT - 1 year ago

Collegium Reports Second Quarter 2024 Financial Results

Collegium to Acquire Ironshore Therapeutics, Expanding into Neurology

Jul 29, 2024, 6:00 AM EDT - 1 year ago

Collegium to Acquire Ironshore Therapeutics, Expanding into Neurology

Collegium to Participate in Jefferies Global Healthcare Conference

May 29, 2024, 8:00 AM EDT - 1 year ago

Collegium to Participate in Jefferies Global Healthcare Conference

Collegium Announces $35 Million Accelerated Share Repurchase Program

May 13, 2024, 8:00 AM EDT - 1 year ago

Collegium Announces $35 Million Accelerated Share Repurchase Program

Collegium Pharmaceutical, Inc. (COLL) Q1 2024 Earnings Call Transcript

May 9, 2024, 7:32 PM EDT - 1 year ago

Collegium Pharmaceutical, Inc. (COLL) Q1 2024 Earnings Call Transcript

Collegium Reports First Quarter 2024 Financial Results

May 9, 2024, 4:02 PM EDT - 1 year ago

Collegium Reports First Quarter 2024 Financial Results

Collegium to Report First Quarter 2024 Financial Results on May 9, 2024

Apr 25, 2024, 8:00 AM EDT - 1 year ago

Collegium to Report First Quarter 2024 Financial Results on May 9, 2024

Collegium Pharmaceutical, Inc. Announces Redemption of Outstanding 2.625% Convertible Senior Notes Due 2026

Apr 11, 2024, 8:00 AM EDT - 1 year ago

Collegium Pharmaceutical, Inc. Announces Redemption of Outstanding 2.625% Convertible Senior Notes Due 2026

Top 10 Small-Cap Stocks (SA Quant)

Mar 12, 2024, 5:00 AM EDT - 1 year ago

Top 10 Small-Cap Stocks (SA Quant)

ANIP APOG BLBD GCT PLMR RAMP RDCM

Collegium Pharmaceutical's (COLL) Q4 2023 Earnings Call Transcript

Feb 22, 2024, 9:52 PM EST - 1 year ago

Collegium Pharmaceutical's (COLL) Q4 2023 Earnings Call Transcript

Collegium Reports Record Fourth Quarter and Full-Year 2023 Financial Results

Feb 22, 2024, 4:09 PM EST - 1 year ago

Collegium Reports Record Fourth Quarter and Full-Year 2023 Financial Results

Collegium to Report Fourth Quarter and Full-Year 2023 Financial Results on February 22, 2024

Feb 8, 2024, 8:00 AM EST - 2 years ago

Collegium to Report Fourth Quarter and Full-Year 2023 Financial Results on February 22, 2024

Appeals Court Upholds PTAB's Finding of Invalidity of Purdue's 961 Patent

Nov 27, 2023, 8:00 AM EST - 2 years ago

Appeals Court Upholds PTAB's Finding of Invalidity of Purdue's 961 Patent

Collegium Pharmaceutical, Inc. (COLL) Q3 2023 Earnings Call Transcript

Nov 7, 2023, 10:15 PM EST - 2 years ago

Collegium Pharmaceutical, Inc. (COLL) Q3 2023 Earnings Call Transcript

Collegium Reports Third Quarter 2023 Financial Results

Nov 7, 2023, 4:01 PM EST - 2 years ago

Collegium Reports Third Quarter 2023 Financial Results

Collegium Pharmaceutical: Delivering On Promises

Oct 24, 2023, 2:59 PM EDT - 2 years ago

Collegium Pharmaceutical: Delivering On Promises

jewell69
jewell69 Dec. 25 at 1:17 AM
$COLL did everybody see it was up 6.5% today 12/24/25
0 · Reply
volflux
volflux Dec. 18 at 12:55 PM
$COLL
0 · Reply
JarvisFlow
JarvisFlow Dec. 9 at 3:37 PM
Barclays has adjusted their stance on Collegium Pharmaceutical ( $COLL ), setting the rating to Overweight with a target price of 58.
0 · Reply
Estimize
Estimize Nov. 24 at 1:03 PM
Wall St is expecting 2.14 EPS for $COLL Q4 [Reporting 02/19 BMO] http://www.estimize.com/intro/coll?chart=historical&metric_name=eps&utm_co
0 · Reply
KirRoyalTrader
KirRoyalTrader Nov. 23 at 10:02 PM
$UVE $INVA $COLL $APPN
0 · Reply
evanmedeiros
evanmedeiros Nov. 23 at 5:10 PM
Nice high tight flag setting up here in Collegium Pharmaceutical. Watchlists still loaded with pharma stocks as technology continues its sell off. Chart found from @InvestorsBusinessDaily MarketSurge https://research.investors.com/stock-quotes/nasdaq-COLL-inc-COLL.htm?utm_source=Evan_Medeiros&utm_medium=stocktwits&utm_campaign=SOCIAL+INFLUENCER&utm_id=SCINFLUENCER&utm_content=leaderboard#performance%3Fsrc=A00616 $COLL #IBDPartner
0 · Reply
ZacksResearch
ZacksResearch Nov. 21 at 1:14 PM
2025 could be the momentum shift $COLL investors have been waiting for. Bold buybacks, a refreshed board, and an expanding ADHD push are all lining up to make this a truly dynamic, transformative year. Full breakdown here 👉 https://www.zacks.com/stock/news/2794020/why-2025-is-a-dynamic-and-transformative-year-for-collegium?cid=sm-stocktwits-2-2794020-teaser-21968&ADID=SYND_STOCKTWITS_TWEET_2_2794020_TEASER_21968
0 · Reply
ZacksResearch
ZacksResearch Nov. 21 at 12:14 PM
$COLL outshines with a 53.4% YTD gain! 🚀 ✨ Q3 2025 adjusted EPS of $2.25 beats the Zacks Consensus Estimate of $1.88. 📊 Revenue for Q3 2025 hits $209.36M, topping consensus & improving from $159.3M a year ago. 💪 Zacks Rank #1 (Strong Buy) highlights their strategic growth initiatives. Discover the full growth story here 👉 https://www.zacks.com/stock/news/2794020/why-2025-is-a-dynamic-and-transformative-year-for-collegium?cid=sm-stocktwits-2-2794020-body-21967&ADID=SYND_STOCKTWITS_TWEET_2_2794020_BODY_21967
0 · Reply
JR603
JR603 Nov. 12 at 10:14 PM
$COLL Could this be a BO? It's tempting to cash out after all these LONG years ..... BUT what if it's going to be offered to be bought at a 50% premium? That would be just my luck!!!
1 · Reply
Itinerant
Itinerant Nov. 7 at 9:55 PM
$COLL I understand that some investors fear the risk of the opiod litigation and its potential damage to the valuation of COLL. I have added $500 million of such cost into the balance sheet of COLL, and I want to tell you that such a liability is not of serious consequence to the overall valuation of COLL. The company is substantially under valued and can absorb such a settlement cost without difficulty. Of course, I do not really know what such a settlement might prove to be. I am just guessing a number. But you get the idea. Having said that, the market will likely over react to any such settlement, as the market almost always over reacts. JMO
0 · Reply
MarkNewtonCMT
MarkNewtonCMT Nov. 7 at 9:45 PM
$COLL Collegium Pharma (Gen.Drugs) popped this week out of a tight Cup and Handle formed back in early 2024 and one to certainly keep an eye on going forward. This @marketsurge chart by @IBDinvestors is on William O Neill's screen (85 stocks) & given Healthcare's success lately, still looks technically attractive on this high volume breakout. @InvestorsBusinessDaily
0 · Reply
jewell69
jewell69 Nov. 7 at 6:58 PM
$COLL sold yesterday 11/6 on great earns day 11/06/2025 Sell Trade Details COLL COLLEGIUM PHARMACEUTICAL 51 $40.05 $0.01 $2,042.54 up even more today, friday 11/7/25 1:54 pm est 42.31 +another 4.06% for the day
0 · Reply
JarvisFlow
JarvisFlow Nov. 7 at 3:51 PM
Truist Securities has adjusted their stance on Collegium Pharmaceutical ( $COLL ), setting the rating to Buy with a target price of 45 → 48.
0 · Reply
JarvisFlow
JarvisFlow Nov. 7 at 11:41 AM
HC Wainwright & Co. updates rating for Collegium Pharmaceutical ( $COLL ) to Action List Buy, target set at 44 → 46.
0 · Reply
d_risk
d_risk Nov. 6 at 4:40 PM
$COLL - Collegium Pharmaceutical Inc. Common Stock - 10Q - Updated Risk Factors COLL’s latest 10-Q expands risk disclosures, highlighting increased concerns over debt, product commercialization, regulatory hurdles, IP litigation, manufacturing reliance, market acceptance, opioid litigation, competition, cybersecurity, AI, and stock volatility. #Pharmaceuticals #MarketVolatility #Cybersecurity #OpioidLitigation #RegulatoryRisk 🟢 Added 🟠 Removed https://d-risk.ai/COLL/10-Q/2025-11-06
0 · Reply
jewell69
jewell69 Nov. 6 at 2:43 PM
$COLL trades since september, 2025 9/12 b 101 38.24 10/20 s 50 33.98 able to do a quickie here 10/20 again b 50 33.61 cheaper than 33.98 sale earlier in the day. 10/20 AGAIN S 50 34.11. Now I am resigned to just getting out of half of it at an overall loss s 51 today 11/6 40.05 net net 106.24 loss
0 · Reply
jewell69
jewell69 Nov. 6 at 1:58 PM
$COLL got painkillers ? - Earnings Flash (COLL) Collegium Pharmaceutical Posts Q3 Adjusted EPS $2.25, vs. FactSet Est of $1.86 stock is up in pre-market.
0 · Reply
Stefan100
Stefan100 Nov. 6 at 1:10 PM
$COLL the company is continuing to execute and upped its guidance https://ir.collegiumpharma.com/news-releases/news-release-details/collegium-reports-third-quarter-2025-financial-results-raises
1 · Reply
Doozio
Doozio Nov. 6 at 12:50 PM
$COLL or this morning as da huckleberries are thru da $$$$ during 🐒🍌🧠⏰♾️
0 · Reply
Doozio
Doozio Nov. 5 at 7:48 PM
$COLL eps 2nte? 🐒🍌🧠⏰♾️
0 · Reply
WilkinsRF
WilkinsRF Oct. 20 at 9:53 PM
$COLL right near 35 from under 31. With this momentum we could be at new highs from earnings or before
0 · Reply
WilkinsRF
WilkinsRF Oct. 15 at 9:11 PM
$COLL reversal of flush out in progress. 35 to 40 could come fast
0 · Reply